Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorośli pacjenci (18 lat i więcej) ze zdiagnozowanym rakiem tarczycy
- •Pacjenci, którzy mieli całkowicie usuniętą tarczycę
- •Pacjenci z przerzutami raka lub podejrzeniem przerzutów
- •Pacjent i lekarz planują leczenie radioaktywnym jodem
- •Nowotwór widoczny i zmierzony w ciągu ostatnich 6 miesięcy (USG, MRI, PET/CT lub tomografia)
✗ Disqualifies
- •Osoby poniżej 18 lat
- •Kobiety w ciąży
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, United States
Trial contact
Ravinder Grewal, MD
Steven Larson, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.